SNG-1153 is a second generation small molecule based on the structure of icaritin. It was selected to target ER-alpha 36 enriched tumor cells. The preclinical results show that SNG-1153 has anti-tumor activity in endometrial and breast cancer models. We are ready to file IND by the end of 2014.

SNG-8023 is ER-alpha 36 monoclonal antibody. It has high specificity and affinity of membrane ER-alpha 36, and can be efficiently internalized by tumor cells. SNG-8023 based antibody therapeutic has potential for multiple indications: liver cancer, leukemia and breast cancer. ADC work is ongoing and IHC diagnostic work is initiated.